SPOTLIGHT: Spectrum outlines trial design


Spectrum Pharmaceuticals has reached agreement with the FDA on two late-stage studies of its bladder cancer drug EOquin. The primary goal will be a statistically significant difference in the rate of tumor reoccurrence. Release